LAG3 and melanoma: In a global phase I/II clinical trial involving LAG3 in untreated advanced melanoma, patients treated with anti-LAG3 in combination with anti-PD-1 exhibited a median progression-free survival of 10.1 months compared to 4.6 months in an anti-PD1-only treatment group [130].